ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -0.96% and +9.10%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?